Evidence map›Paper›PMID 38578080›Full record

ArticleAntimicrobial agents and chemotherapy2024

Prospective validation of a model-informed precision dosing tool for vancomycin treatment in neonates.

Riste Kalamees, Hiie Soeorg, Mari-Liis Ilmoja, Kadri Margus, Irja Lutsar, Tuuli Metsvaht

Abstract readValidation Study
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. State of Vancomycin Dosing in Neonates: An Overview.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Riste KalameesDepartment of Microbiology, University of Tartu, Tartu, Estonia.
Hiie SoeorgDepartment of Microbiology, University of Tartu, Tartu, Estonia.
Mari-Liis IlmojaPediatric and Neonatal Intensive Care Unit, Tallinn Children's Hospital, Tallinn, Estonia.
Kadri MargusDepartment of Neonatology, East Tallinn Central Hospital, Tallinn, Estonia.
Irja LutsarDepartment of Microbiology, University of Tartu, Tartu, Estonia.
Tuuli MetsvahtDepartment of Microbiology, University of Tartu, Tartu, Estonia.ORCID 0000-0003-3206-3092

Funding

Tartu University Hospital 562/2021
6 · The paper itself

Abstract

We recruited 48 neonates (50 vancomycin treatment episodes) in a prospective study to validate a model-informed precision dosing (MIPD) software. The initial vancomycin dose was based on a population pharmacokinetic model and adjusted every 36-48 h. Compared with a historical control group of 53 neonates (65 episodes), the achievement of a target trough concentration of 10-15 mg/L improved from 37% in the study to 62% in the MIPD group (

Indexed as

Anti-Bacterial AgentsVancomycinFemaleHumansInfant, NewbornMaleProspective StudiesSoftwareAnti-Bacterial AgentsVancomycinmodel-informed precision dosingneonatesvancomycin

Identifiers

PMID38578080
PMCPMC11064528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.